Verily, Alphabet’s life biotech division formerly known as Google life sciences, is teaming up with ResMed to study and explore treatments for sleep apnea.
ResMed makes remote monitoring devices and software for sleep apnea patients. Combined with Verily’s data analytics technologies, the companies will try to drill down on the health and financial impacts of undiagnosed and untreated sleep apnea.
The goal is to develop software that can be used by healthcare professionals to identify, diagnose, treat, and manage sleep apnea in patients.
Interestingly, the companies are formalizing their partnership as a full scale joint venture, complete with customary closing conditions and regulatory approvals. The joint venture will be based in the U.S. and operate as a separate venture from ResMed and Verily, the companies said.
